The expression of PD-L1 in salivary gland carcinomas.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
04 09 2019
Historique:
received: 17 10 2018
accepted: 21 08 2019
entrez: 6 9 2019
pubmed: 6 9 2019
medline: 5 11 2020
Statut: epublish

Résumé

Objective was to analyze the role of PD-L1 and its relation to demographic, patho-clinical and outcome parameters in salivary gland carcinoma (SGC) patients. Patients treated for salivary gland carcinomas between 1994 and 2010 were included. A retrospective chart review for baseline characteristics, pathohistological, clinical and outcome data was performed. Immunohistochemistry for PD-L1 was performed using tissue microarrays. PD-L1 expression was assessed in tumor cells and tumor-infiltrating immune cells (TIIC) and statistical analysis with regard to baseline and outcome data was performed. Expression of PD-L1 (by means ≥1% of the cells with PD-L1 positivity) was present in the salivary gland carcinoma cells of 17%, in the TIIC of 20% and in both tumor cells and TIIC of 10% the patients. PD-L1 expression in tumor cells and both tumor cells and TIIC was related to tumor grading (p = 0.035 and p = 0.031, respectively). A trend towards higher grading was also seen for PD-L1 expression in TIICs (p = 0.058). Patients with salivary duct carcinomas and PD-L1 expressing TIICs showed a significantly worse DFS and OS (p = 0.022 and p = 0.003, respectively), those with both tumor cells and TIIC expressing PD-L1 a significantly worse DFS (p = 0.030). PD-L1 expression is present in 17% and 20% of salivary gland carcinoma cells and TIIC. Ten percent of the patient showed a PD-L1 positivity in both tumor cells and TIIC. This is related to high tumor grading and therefore might be a negative prognostic factor.

Identifiants

pubmed: 31484986
doi: 10.1038/s41598-019-49215-9
pii: 10.1038/s41598-019-49215-9
pmc: PMC6726636
doi:

Substances chimiques

B7-H1 Antigen 0
Biomarkers, Tumor 0
CD274 protein, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

12724

Références

Immunol Lett. 2006 Feb 15;102(2):222-8
pubmed: 16236366
Sci Transl Med. 2012 Mar 28;4(127):127ra37
pubmed: 22461641
Strahlenther Onkol. 2017 Nov;193(11):961-970
pubmed: 28828496
Otolaryngol Head Neck Surg. 2003 Dec;129(6):720-5
pubmed: 14663441
Laryngoscope Investig Otolaryngol. 2018 Apr 19;3(3):182-190
pubmed: 30062133
Neoplasia. 2006 Mar;8(3):190-8
pubmed: 16611412
Clin Cancer Res. 2005 Apr 15;11(8):2947-53
pubmed: 15837746
Cancer Immunol Res. 2016 Aug;4(8):679-87
pubmed: 27312343
Cancer Res Treat. 2016 Apr;48(2):527-36
pubmed: 26511814
Cancer Immunol Res. 2013 Jul;1(1):54-63
pubmed: 24416729
J Mol Med (Berl). 2003 May;81(5):281-7
pubmed: 12721664
Oral Oncol. 2014 Jul;50(7):627-32
pubmed: 24819861
Nat Rev Cancer. 2016 May;16(5):275-87
pubmed: 27079802
J Oral Pathol Med. 2016 Oct;45(9):655-663
pubmed: 27037970
J Clin Pathol. 2003 Dec;56(12):914-8
pubmed: 14645349
Ann Pathol. 2017 Feb;37(1):79-89
pubmed: 28111039
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7
pubmed: 12218188
Cancer. 2005 Jun 15;103(12):2526-33
pubmed: 15900577
Lancet Oncol. 2011 Aug;12(8):815-24
pubmed: 21147032
Oral Dis. 2002 Sep;8(5):229-40
pubmed: 12363107
Arch Oral Biol. 2017 Nov;83:55-62
pubmed: 28711734
J Surg Oncol. 2016 Jul;114(1):36-43
pubmed: 27111278
Cancer Control. 2014 Jul;21(3):231-7
pubmed: 24955707
J Otolaryngol Head Neck Surg. 2016 May 16;45(1):32
pubmed: 27184361
Cancer Immunol Res. 2014 Apr;2(4):361-70
pubmed: 24764583
Int J Radiat Oncol Biol Phys. 1997 Jan 1;37(1):79-85
pubmed: 9054880
Acta Otolaryngol. 2002 Oct;122(7):758-64
pubmed: 12484654
Oral Oncol. 2014 Nov;50(11):e64-6
pubmed: 25218000
Cancer. 1981 Feb 15;47(4):645-8
pubmed: 7194729
Ann Surg Oncol. 2016 Jun;23(6):2038-45
pubmed: 26790669
Cancer. 1984 Sep 15;54(6):1062-9
pubmed: 6088017
J Oral Pathol Med. 2018 Aug;47(7):683-690
pubmed: 29719073
Hum Pathol. 2016 Jan;47(1):52-63
pubmed: 26527522
Nat Med. 2002 Aug;8(8):793-800
pubmed: 12091876
Arch Pathol Lab Med. 2009 Nov;133(11):1763-74
pubmed: 19886710
Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):103-11
pubmed: 15629600
Br J Dermatol. 2017 May;176(5):1354-1356
pubmed: 27516151
J Cutan Pathol. 2016 Aug;43(8):663-70
pubmed: 27153517
Cancer Res. 2013 Jan 1;73(1):128-38
pubmed: 23135914
Pathologe. 2016 Nov;37(6):557-567
pubmed: 27510417
Oral Oncol. 2017 Aug;71:41-46
pubmed: 28688689
Otolaryngol Head Neck Surg. 2016 Jun;154(6):1041-6
pubmed: 26980918
Int J Cancer. 2016 Jul 15;139(2):396-403
pubmed: 26945902
Cancer Res. 2013 Mar 15;73(6):1733-41
pubmed: 23288508
BMC Cancer. 2018 Feb 6;18(1):156
pubmed: 29409471

Auteurs

Domenic Vital (D)

Department of Otorhinolaryngology, Head and Neck Surgery, Zurich University Hospital and University of Zurich, Frauenklinikstrasse 24, CH-8091, Zurich, Switzerland. domenic.vital@usz.ch.

Kristian Ikenberg (K)

Department of Pathology and Molecular Pathology, Zurich University Hospital and University of Zurich, Schmelzbergstrasse 12, CH-8091, Zurich, Switzerland.

Holger Moch (H)

Department of Pathology and Molecular Pathology, Zurich University Hospital and University of Zurich, Schmelzbergstrasse 12, CH-8091, Zurich, Switzerland.

Matthias Rössle (M)

Department of Pathology, Luzerner Kantonsspital, Spitalstrasse, CH-6000, Lucerne 16, Switzerland.

Gerhard F Huber (GF)

Department of Otorhinolaryngology, Head and Neck Surgery, Kantonsspital St. Gallen, Rorschacher Strasse 95, CH-9007, St. Gallen, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH